$1.28
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
Overview
52-week range
$0.64
$1.86
52% of range
Avg surprise (last 3)
+13.3%
Avg reaction (last 2)
+1.8%
100% positive
Latest IV / EM
1791%
EM ±299.2% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.08 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.04 | $-0.10 | +60.0% | +60.0% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.12 | $-0.10 | -20.0% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.10 | $-0.10 | 0.0% | — | +3.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.11 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.09 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.11 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.10 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.11 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | $10M | — | $7M | $9M | $10M | — | $8M |
| Cost of revenue | $2M | $2M | — | $2M | $2M | $1M | — | $2M |
| Gross profit | $6M | $8M | — | $5M | $7M | $9M | — | $6M |
| Operating income | $-10M | $-6M | — | $-14M | $-14M | $-12M | — | $-14M |
| Net income | $-9M | $-5M | — | $-12M | $-12M | $-10M | — | $-12M |
| EPS (diluted) | $-0.08 | $-0.04 | — | $-0.12 | $-0.12 | $-0.10 | — | $-0.11 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15M | $15M | $20M | $13M | $15M | $23M | $28M | $37M |
| Inventory | $8M | $8M | $8M | $8M | $8M | $8M | $9M | $10M |
| Total current assets | $121M | $123M | $118M | $125M | $143M | $156M | $172M | $173M |
| Total assets | $185M | $194M | $203M | $213M | $220M | $230M | $239M | $249M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $26M | $27M | $31M | $33M | $29M | $31M | $33M | $35M |
| Total equity | $159M | $168M | $171M | $180M | $191M | $199M | $206M | $213M |